Updated 11 June 2026 · Reviewed by IFRS Buddy Editorial Team
When the terms of an equity-settled award are modified, an entity must recognise, at a minimum, the services received measured at the original grant-date fair value. If the modification increases the total fair value or is otherwise beneficial to the employee, recognise the incremental fair value over the remaining vesting period. If the modification decreases fair value (i.e., is detrimental), ignore it for accounting purposes and continue as if the original terms still apply (IFRS 2.26–27).
A modification is any change to the terms or conditions of a share-based payment arrangement. Common examples:
The accounting treatment depends on whether the modification benefits the employee:
| Type | Effect on fair value | Accounting |
|---|---|---|
| Beneficial (e.g., repricing) | Increases FV | Recognise original grant-date FV + incremental FV |
| Neutral | No change in FV | Continue recognising original grant-date FV |
| Detrimental (e.g., increasing exercise price) | Decreases FV | Ignore — continue on original terms |
Incremental fair value = fair value of modified award immediately after modification − fair value of original award immediately before modification.
The incremental fair value is spread over the remaining vesting period from the modification date.
When vesting is accelerated — for example, on a change of control or on termination — the entity must recognise immediately all remaining expense that would otherwise have been recognised over the original vesting period.
The unrecognised grant-date fair value is charged to profit or loss at the acceleration date, with a corresponding credit to equity.
If an equity-settled award is cancelled and replaced with a cash payment, the entity:
Original grant: 5,000 options, exercise price €30, grant-date FV €6, 4-year vesting, 2 years remaining.
Situation: after 2 years the share price has fallen to €14. The company reprices the options to €16.
Step 1 — Fair value immediately before repricing (original terms, share price €14): €1.20 per option.
Step 2 — Fair value immediately after repricing (new exercise price €16, share price €14): €3.50 per option.
Step 3 — Incremental fair value: €3.50 − €1.20 = €2.30 per option.
| Period | Original grant-date FV (remaining) | Incremental FV | Total charge |
|---|---|---|---|
| Remaining 2 years | 5,000 × €6 × 2/4 = €15,000 | 5,000 × €2.30 × 2/2 = €11,500 | €26,500 |
| Per year | €7,500 | €5,750 | €13,250 |
| Account | Dr (€) | Cr (€) |
|---|---|---|
| Share-based payment expense | 13,250 | |
| Share-based payment reserve (Equity) | 13,250 |
Setup: Employee holds 1,000 RSUs, grant-date FV €40, 3-year vesting. The employee is made redundant at end of year 1 with immediate vesting of all awards.
Expense recognised in year 1 (before acceleration): 1,000 × €40 × 1/3 = €13,333.Remaining unrecognised: 1,000 × €40 × 2/3 = €26,667.
| Account | Dr (€) | Cr (€) |
|---|---|---|
| Share-based payment expense | 26,667 | |
| Share-based payment reserve (Equity) | 26,667 |
Total recognised: €40,000 = full grant-date fair value, consistent with full vesting.
If an award is cancelled outright (not replaced, not cash-settled):
This treatment is identical to the acceleration of vesting — cancellation accelerates the expense, it does not eliminate it.